Professional Experience
Her professional roles reflect both leadership in clinical oncology and involvement in research and trial work.
- Current: Head of the Gynecologic Medical Oncology Unit, Department of Gynecology & Obstetrics, IRCCS San Raffaele, Milan
- Leader of Oncofertility pathway (“Maternità e Tumori”) for patients needing fertility preservation
- Principal Investigator in multiple Phase II and Phase III domestic and international trials, under Good Clinical Practice standards
- Member of the MITO Group (Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies), directing rare tumors commission
Academic Contributions
Dr. Mangili combines patient care with rich academic, research, and teaching activity:
- Lecturer and tutor in the Residency program in Obstetrics & Gynecology at Vita‑Salute San Raffaele University
- Supervision of medical students, residents, especially in gynecologic oncology
- Research focuses on innovative drug therapies in gynecologic oncology, rare tumors, and fertility preservation
- Invited speaker in international conferences; contributions to chapters in oncology textbooks
Areas of Expertise
She is recognized for her clinical excellence in several specialized domains:
- Treatment of ovarian, endometrial, cervical cancers
- Management of cancer during pregnancy
- Therapies for rare gynecologic tumors and trophoblastic disease
- Strategies for fertility preservation: oocyte cryopreservation, ovarian tissue preservation, counseling
- Risk prediction for loss of ovarian function after chemotherapy
Publications and Research
Dr. Mangili has a solid research record with impactful publications:
- Approx. 150 peer‑reviewed articles in national and international scientific journals
- H‑index of 30
- Key recent works:
- “Fertility preservation in female cancer patients: a single center experience” – summarizing oncofertility data for nearly 100 patients from San Raffaele Unit over 3 years. Refers techniques like oocyte and tissue cryopreservation.
- “Ovarian failure risk in post‑pubertal patients with cancer: a prognostic model” – a predictive model based on age, treatment lines, and agents, with high accuracy (AUC ~0.906).
- “Consolidation courses in low‑risk gestational trophoblastic neoplasia and relapse rate: MITO‑9 retrospective study” (2025) – studying relapse rates under specific consolidation treatment.
Patient Care Philosophy
Dr. Mangili’s approach to patient care is marked by empathy, precision, and comprehensive support:
- Strong emphasis on clear communication: explaining treatment options, risks, and realistic outcomes
- Shared decision‑making, particularly when balancing cancer treatment with preserving fertility
- Holistic patient support: co‑founded Salute allo Specchio Onlus in 2013 to address psychological, aesthetic, and psychomotor impacts of cancer treatment
- Commitment to multidisciplinary care, bringing together oncologists, gynecologists, reproductive specialists, and support services
Professional Affiliations
Dr. Mangili holds membership and leadership positions in several scientific and clinical institutions:
- Member, European Society of Gynecologic Oncology (ESGO)
- Member, European Organization for Treatment of Trophoblastic Disease (EOTTD)
- Member, Italian Association of Medical Oncology (AIOM)
- Board Member, MITO Group (rare tumors commission)
- Involved in teaching roles and institutional committees at San Raffaele and university affiliates
FAQs
- Is Dr. Giorgia Mangili board‑certified?
- Yes. She holds specializations in Obstetrics & Gynecology and Oncology, and in 2017 obtained national qualification for full professorship.
- What cancers does she treat?
- She treats gynecologic cancers (ovarian, cervical, endometrial), rare tumors, tumors during pregnancy, and trophoblastic disease.
- Does she offer fertility preservation?
- Yes. She leads the oncofertility unit and offers oocyte and ovarian tissue cryopreservation as well as counseling and predictive risk models.
- Does she accept international patients?
- Yes. She works in a major research hospital in Milan with international collaborations; patients from abroad can access her clinical services depending on institutional policies.
- What languages does she speak?
- She speaks Italian and English.
- How significant is her research output?
- Her output includes ~150 articles, an H‑index of 30, leadership in trials (MITO group), and several studies visible in international journals.
- What is the risk model for ovarian failure?
- She co‑authored research developing a predictive model for ovarian failure based on factors such as age, number of chemotherapy lines, and specific agents; this model shows high reliability.
